NCT00030472终止2 期
A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 试验地点
- 34
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.
详细描述
OBJECTIVES:
- Determine the antitumor activity of doxorubicin HCl liposome in patients with persistent or recurrent squamous cell carcinoma of the cervix.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive doxorubicin HCl liposome IV over 1 hour on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (34)
Loading locations...
相似试验
已完成
2 期
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaSarcomaNCT00020449National Cancer Institute (NCI)
已完成
3 期
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerOvarian CancerPeritoneal Cavity CancerNCT00043082SWOG Cancer Research Network61
终止
1 期
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00003380Gynecologic Oncology Group
已完成
1 期
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's LymphomaLymphomaNCT00004162University of Alabama at Birmingham48
已完成
2 期
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaLymphomaNCT00006125Alliance for Clinical Trials in Oncology